Cloudbreak Pharma Inc. (HKG:2592)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.18
+0.10 (1.97%)
At close: Aug 12, 2025, 4:00 PM HKT
1.97%
Market Cap4.25B
Revenue (ttm)77.68M
Net Income (ttm)-769.99M
Shares Out838.89M
EPS (ttm)-1.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume289,500
Average Volume652,530
Open5.08
Previous Close5.08
Day's Range5.04 - 5.20
52-Week Range5.01 - 9.74
Betan/a
RSI34.19
Earnings Daten/a

About Paramount Global

Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingre... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 51
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2592
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.